LUNG CANCER
Conditions
Brief summary
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Interventions
BIOLOGICAL23-valent pneumococcal vaccine
Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients \>=18 years of age; 2. Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received pneumococcal vaccine
Exclusion criteria
Patients having other factors that preventing researchers from enrollment them.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of pneumonia at 12 months | 12 months | During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests. |
| Incidence of pneumonia | 24 months | The proportion of lung cancer patients who developed pneumonia during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival rate | 5 years | The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Antibiotic usage | 5 years | This includes the types, dosages, and durations of antibiotic usage, etc |
| Quality of life of lung cancer patients | 5 years | Specific quality of life assessment scales are used, such as standardized quality of life assessment tools (such as EORTC QLQ-C30) to evaluate the quality of life of patients. |
| Lung cancer-related complications | 5 years | The incidence of complications related to lung cancer (such as respiratory failure, infection, etc.). |
| Adverse reactions after vaccination | 30 days | Observe whether patients who receive the 23-valent pneumococcal vaccine experience adverse reactions after vaccination, such as fever, redness, swelling and pain at the injection site, headache, dizziness, etc. |
| Immune response | 5 years | The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing. |
| Length of hospital stay | 5 years | Record the number of days of hospitalization for patients hospitalized due to lung infection. |
| Hospitalization rate | 5 years | The proportion of patients hospitalized due to pneumonia or other related complications. |
Outcome results
None listed